Oncology Revenue Cycle: Preventing Catastrophic Denials on Buy-and-Bill Drug Claims

‍

In oncology, a single denied or underpaid regimen is a cash event, not a rounding error. Buy-and-bill drug and infusion claims are large enough that one avoidable error can move the month.

TL;DR

• Buy-and-bill and infusion claims are enormous, so a denial is catastrophic, not routine.
• J-code billing is unforgiving on units, wastage, and NDC detail, and small errors trigger large denials.
• Thin ASP margins mean underpayments slip through unless every claim is reconciled against the contract.

Why One Denied Regimen Is a Cash Event

The economics of oncology are different from most specialties. When the drug on the claim can cost more than a month of a typical practice's other revenue, a denial is not something you absorb and move past. It is a direct hit to cash and to margin, and it happens on claims where the error was almost always preventable.

Where Buy-and-Bill Claims Leak

J-code detail: units, wastage, and NDC

J-code and drug billing is unforgiving. Units, wastage, and NDC details all have to be exact. A small clerical error on a high-value drug triggers a large denial, and the dollar value at stake makes it the most common and most expensive failure point in oncology billing. Unit counts and documented wastage must be precise, and the National Drug Code on the claim must match the drug administered exactly. A mismatch in any of these fields is a fast route to a denied claim that should never have left the billing queue in that condition.

Authorization, step therapy, and pathways

Authorization, step-therapy, and pathway requirements on drugs and imaging are constant, and payer policy shifts faster than a general team can track. A single missed requirement on a high-value regimen turns a large claim into a denial before treatment revenue is ever collected.

Underpayments on ASP-based drugs

Reimbursement on ASP-based drugs is thin, so underpayments slip through unless someone is reconciling every claim against the contract. On oncology volumes, the quiet gap between what you were paid and what you were owed adds up to real money every month.

The Quiet Leak: Underpayment Reconciliation

Denials are visible because a claim comes back. Underpayments are worse in one respect: the claim is paid, just not fully, so nothing flags it. Without line-by-line reconciliation against contracted rates, that margin is simply gone.

‍

Thin Margins, High Stakes

With hospital operating margins near 1% and ASP-based drug reimbursement already thin, an unreconciled underpayment is a margin you will not get back unless someone is checking every claim against the contract.

How Flow Services Closes These Gaps

Oncology billing requires a level of drug-billing QA, authorization tracking, and payment reconciliation that most general RCM teams are not configured to deliver at the required precision. Flow Services, powered by CaduceusHealth, brings certified onshore coding and denials specialists into your athenahealth workflow alongside your existing team, starting with the one service where revenue is leaking most, without disrupting how the practice currently operates.

CaduceusHealth's certified experts handle J-code QA, authorization, and step-therapy tracking, and line-by-line reconciliation against contracted rates. AI amplifies that work, clearing routine volume so specialists spend their time on the claims and the edge cases that actually move the margin. The result is more claims worked with fewer manual touches, and a denial rate that falls as the engagement matures.

This is not a rip-and-replace. Flow Services comes in alongside your existing team or vendor, proves value on one service, and expands from there.

Frequently Asked Questions

What causes most oncology drug-claim denials?

Errors in J-code units, wastage, and NDC detail, followed by missing or incorrect authorization and step-therapy requirements. Because the claims are high-value, these denials are costly out of proportion to the size of the mistake.

How do underpayments on ASP drugs go unnoticed?

The claim is paid, so nothing flags it in the worklist. Only a reconciliation of each payment against the contracted rate surfaces the gap, which is why it slips through teams not staffed for it.

Can reconciliation happen inside Athenahealth?

Yes. The goal is not to replace Athenahealth but to add the drug-billing QA and payment reconciliation that the platform is not configured to do on its own for a high-cost drug book.

The lowest-friction next step is not a demo or a rip-and-replace. It is a read on your own numbers. A diagnostic assessment takes your Athenahealth claims data and returns a revenue opportunity report that puts a dollar figure on every gap, at no cost and with no commitment. It is a read on your own tablespace from Flow Services, powered by CaduceusHealth, the 10th largest athenahealth client, supporting 3,500+ providers with nearly three decades of athenahealth-native revenue cycle work.